
-
Drug cheats put India Olympic bid and careers at risk
-
East Timor police fire tear gas on second day of car purchase protests
-
Austria hit with fresh spy claims after govt promises law change
-
Floods devastate India's breadbasket of Punjab
-
In mega-city Lagos, 20 million count on just 100 ambulances
-
FBI chief Kash Patel faces Senate panel
-
Trump says bringing $15 bn lawsuit against New York Times
-
Israel sets Gaza 'on fire' as Rubio warns days left for deal
-
Phillies clinch first MLB division by beating Dodgers
-
'Nothing here': Lack of jobs forces young Nepalis abroad
-
Rubio asks Qatar to stay as mediator after Israeli strike
-
Trump set for unprecedented second UK state visit
-
Lower US tariffs on Japan autos kick in
-
Revamped Bayern face early test as Chelsea come to town
-
Papua New Guinea, Australia to vow mutual defence in new treaty
-
Malawi election a battle of two presidents
-
Asian markets rise as traders prepare for expected US rate cut
-
Malawi votes in a rematch between two presidents as economic crisis bites
-
Australia says social media ban will not age test all users
-
Poland's Nawrocki talks drone defence in Paris and Berlin
-
Trump's fossil fuel agenda challenged in youth climate suit
-
PSG fear impact of injuries as they put Champions League title on the line
-
US Senate confirms Trump aide to Fed as politics loom over rate meeting
-
Papua New Guinea, Australia will commit to mutual defence
-
Trash, mulch and security: All jobs for troops in Washington
-
Why Leaders Across Industries Are Trusting and Building Good Driver Mutuality
-
Tocvan Announces Commencement Of Field Work And Airborne Magnetics Survey At Gran Pilar Gold Silver Project; Drilling And Trenching Prep Accelerate Discovery & Pilot Mine Production
-
NFL legend Brady to play in March flag football event at Riyadh
-
Lower US tariffs on Japan autos to take effect Tuesday
-
US strikes second alleged Venezuelan drug boat as tensions mount
-
Protesting Peru residents block trains to Machu Picchu
-
US strikes another alleged Venezuelan drug boat as tensions rise
-
White House vows to take on left-wing 'terror' movement after Kirk killing
-
Brazil's Amazon lost area the size of Spain in 40 years: study
-
US Senate poised to advance Trump aide's appointment at Fed
-
Sri Lanka survive Hong Kong scare for four wicket Asia Cup win
-
Arab, Muslim leaders urge review of Israel ties after Qatar attack
-
Mbappe 'not anxious' over Champions League goal as Bellingham returns
-
Huge pot of Nigerian jollof rice sets Guinness record
-
Heartbreak will help Arsenal's Champions League charge: Arteta
-
Europe stumped by Trump demands over Russia sanctions
-
Cycling fears spread of race-halting protests after Vuelta chaos
-
US, China reach 'framework' deal on TikTok ownership
-
'With our fists if necessary': Venezuelans prepare to defend homeland against potential US invasion
-
Duplantis thrives on Tokyo energy to break world record again
-
Ex-France defender Umtiti calls time on club career
-
One in six US parents rejecting standard vaccine schedule: poll
-
Sheffield Utd appoint Wilder for third managerial spell
-
UAE hammer Oman in Asia Cup to keep Super Four hopes alive
-
Activists on trial as France debates right to die

Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
A.Malone--AMWN